WuXi AppTec Co Ltd
SSE:603259
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
36.87
84.24
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
WuXi AppTec Co Ltd
Accrued Liabilities
WuXi AppTec Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
WuXi AppTec Co Ltd
SSE:603259
|
Accrued Liabilities
ÂĄ2.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
Pharmaron Beijing Co Ltd
SZSE:300759
|
Accrued Liabilities
ÂĄ732.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
||
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Accrued Liabilities
ÂĄ393.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
||
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Accrued Liabilities
ÂĄ346m
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
46%
|
||
M
|
MGI Tech Co Ltd
SSE:688114
|
Accrued Liabilities
ÂĄ310.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Accrued Liabilities
ÂĄ74.9m
|
CAGR 3-Years
109%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
WuXi AppTec Co Ltd
Glance View
WuXi AppTec Co., Ltd. is a prominent global healthcare platform that plays a pivotal role in empowering the pharmaceutical, biotechnology, and medical device industries. Founded in 2000 and headquartered in Shanghai, WuXi has cultivated a reputation for excellence through its extensive suite of services, which span the entire drug development lifecycle. From drug discovery to manufacturing, the company leverages cutting-edge technologies and a rich network of expertise to facilitate the development of innovative therapeutics. This comprehensive capability enables WuXi to serve as a trusted partner for clients, helping to streamline the complex path from concept to commercialization. With a focus on innovation and quality, WuXi AppTec has distinguished itself in the competitive landscape of contract research organizations (CROs) and contract manufacturing organizations (CMOs). The company's robust growth trajectory is underpinned by strategic investments in technology and infrastructure, as well as a commitment to expanding its global footprint. WuXi's expansive service offerings not only enhance operational efficiency for its partners but also align with the increasing demand for faster and more cost-effective drug development solutions. For investors, WuXi signifies an opportunity to engage with a market leader poised to capitalize on the burgeoning biopharmaceutical sector, driven by rising global healthcare needs and transformative advancements in science and technology.
See Also
What is WuXi AppTec Co Ltd's Accrued Liabilities?
Accrued Liabilities
2.2B
CNY
Based on the financial report for Jun 30, 2024, WuXi AppTec Co Ltd's Accrued Liabilities amounts to 2.2B CNY.
What is WuXi AppTec Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
26%
Over the last year, the Accrued Liabilities growth was -9%. The average annual Accrued Liabilities growth rates for WuXi AppTec Co Ltd have been 10% over the past three years , 26% over the past five years .